Why Congress should prioritize fixing the 340B program

Nearly all Americans nationwide agree: Lowering out-of-pocket costs for health care should be a top priority for policymakers. Luckily, there are commonsense policies Congress could implement to...
Read More
What they are saying: Nonprofit hospitals are gaming the system at the expense of patients

There have been some alarming stories uncovered by the media on ways nonprofit hospitals — many of which participate in the 340B drug pricing program — are taking advantage of the system and their...
Read More
340B program continues to drive shift in care to more expensive hospital settings

Yet another study highlights the unintended consequences of the 340B program, which is increasing costs for patients and the health care system as a whole. In this case, the Berkeley Research Group...
Read More
New analysis confirms hospitals markup prices for oncology therapies

A recent study from The Journal of the American Medical Association (JAMA) examined 61 hospitals using data made public under new requirements from a recent price transparency regulation. The...
Read More
340B 101: Three charts show the program maximizes hospitals’ bottom line with little consideration for patients

The 340B program was created 30 years ago to support safety-net clinics and qualifying hospitals by establishing a discounted medicine program funded by biopharmaceutical manufacturers. The aim was...
Read More
New report: To drive up profits, hospitals continue unnecessary medicine mark-ups, burdening patients, employers and the health system

A new study from the Employee Benefit Research Institute (EBRI) compared the difference in price for 72 physician-administered outpatient medicines – representing 73% of medicine spending – depending...
Read More
340B hospitals among those that provide lowest levels of community benefit across the country

The 340B program reached $38 billion in sales at the discounted price in 2020. This is a 27% increase over sales in 2019, and the program is now more than four times the size it was in 2014....
Read More
Getting the 340B program back on track in 2021

As our nation continues to fight a global pandemic, the need for access to affordable and quality health care feels even more pressing. This is especially true for vulnerable patients who have been...
Read More
Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients

The New York Times recently ran a story that paints an inaccurate picture of the 340B program, contract pharmacy participation in the program and the biopharmaceutical industry’s commitment to the...
Read More
340B hospitals and for-profit pharmacies generating significant revenue from program meant to help needy patients

The 340B program – a safety-net federal drug program meant to help vulnerable Americans – has become dominated by many large hospitals and for-profit corporations with no clear evidence they are...
Read More